Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
about
Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
description
A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov
@en
klinisch onderzoek
@nl
name
Anti-LAG-3 or Urelumab Alone a ...... ts With Recurrent Glioblastoma
@en
Anti-LAG-3 or Urelumab Alone a ...... ts With Recurrent Glioblastoma
@nl
type
label
Anti-LAG-3 or Urelumab Alone a ...... ts With Recurrent Glioblastoma
@en
Anti-LAG-3 or Urelumab Alone a ...... ts With Recurrent Glioblastoma
@nl
prefLabel
Anti-LAG-3 or Urelumab Alone a ...... ts With Recurrent Glioblastoma
@en
Anti-LAG-3 or Urelumab Alone a ...... ts With Recurrent Glioblastoma
@nl
P1050
P3098
NCT02658981